Treatment response after induction therapy in advanced thymic tumors: results from the Italian nationwide TYME database

Further Publications

Clinical Predictors of Response in Chronic Graft-Versus-Host Disease: Results From the "Predicting the Quality of Response to Specific Treatments (PQRST)" Trial

Am J Hematol

Hamilton BK, Onstad L, Carpenter PA, Pidala J, Chen G, Cutler C, El Jurdi N, Farhadfar N, Juckett M, Kitko CL, Lee CJ, Lee SJ

doi: 10.1002/ajh.70427

Skin Cancer

Comparative cost analysis of a diagnostic multi-omics platform for decision support in advanced cancer - results from the Tumor Profiler Melanoma project

NPJ Precis Oncol

Mehra T, Menges D, Gosztonyi B, Miglino N, Ring A, Boos L, Sobottka B, Tumor Profiler Consortium, Koelzer VH, Moch H, Toussaint NC, Levesque M, Ramelyte E, Mangana J, Dummer R, Wicki A

doi: 10.1038/s41698-025-01229-5

Lung, Respiratory and Thoracic Cancer

Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study

Oncol Ther

Godbert B, Gobbini E, Khalife Y, Decroisette C, Brellier F, Lena H, Fleuriet A, Zysman M, Egenod T, Girard N

doi: 10.1007/s40487-026-00437-8

Lung, Respiratory and Thoracic Cancer

Real-world clinical characteristics and outcomes in patients with HER2-mutant non-small cell lung cancer (NSCLC) who received second-line treatment: A nationwide database analysis in Japan

Lung Cancer

Uehara Y, Ikegami M, Kohsaka S, Kimura H, Mizushima M, Okuma Y

doi: 10.1016/j.lungcan.2026.109491

Leukemia

Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009

J Clin Oncol

Gottschalk H, Möricke A, Conter V, Schrappe M, Starý J, Cario G, Dworzak M, Attarbaschi A, Barbaric D, Locatelli F, Bodmer N, Elitzur S, Silvestri D, Dalla-Pozza L, Bergmann AK, Flotho C, Buldini B, Stanulla M, Izraeli S, Rizzari C, Bourquin JP, Biondi A, Valsecchi MG, Zimmermann M

doi: 10.1200/JCO-25-01357

Genitourinary Cancer

Urine tumor DNA testing identifies recurrence and monitors therapy response in patients with high-risk non-muscle-invasive bladder cancer receiving intravesical bacillus Calmette-Guérin

J Urol

Bahlburg H, Maas M, Contreras-Sanz A, Othman D, St-Laurent MP, Nikkola J, Chai S, Phillips KG, Hamlington B, Lentz PS, Lumbres NP, Bicocca VT, Jalanko T, Levin TG, Lange D, Black PC

doi: 10.1097/JU.0000000000005130

Gastrointestinal Cancer

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648

Ann Oncol

Kato K, Ajani J, Doki Y, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, Hajbi FE, Di Bartolomeo M, Braghiroli MI, Holtved E, Makino T, Murphy MB, Zhang J, Sharma P, He B, Lei M, Matsumura Y, Kitagawa Y, Chau I

doi: 10.1016/j.annonc.2026.08.001

Gastrointestinal Cancer

Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649

Ann Oncol

Janjigian YY, Shitara K, Ajani JA, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary JM, Elimova E, Bruges R, Karamouzis M, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Zander T, Kowalyszyn R, Pazo-Cid R, Schenker M, Feeny K, McCraith S, Hu N, Lei M, Zhang J, Moehler M

doi: 10.1016/j.annonc.2026.02.003

Leukemia

Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study

Leukemia

Fujimoto A, Maeda T, Doki N, Fukuhara N, Iwaki N, Hiramoto N, Goto H, Miyazaki T, Shiki I, Miyazaki K, Yamaguchi M, Ishida F, Suzuki R

doi: 10.1038/s41375-025-02854-6

Related content

Clinical Predictors of Response in Chronic Graft-Versus-Host Disease: Results From the "Predicting the Quality of Response to Specific Treatments (PQRST)" Trial

Comparative cost analysis of a diagnostic multi-omics platform for decision support in advanced cancer - results from the Tumor Profiler Melanoma project

Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study

Real-world clinical characteristics and outcomes in patients with HER2-mutant non-small cell lung cancer (NSCLC) who received second-line treatment: A nationwide database analysis in Japan

Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009

Urine tumor DNA testing identifies recurrence and monitors therapy response in patients with high-risk non-muscle-invasive bladder cancer receiving intravesical bacillus Calmette-Guérin

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648

Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649

Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study